BE1030002B1 - Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire - Google Patents

Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire

Info

Publication number
BE1030002B1
BE1030002B1 BE20216105A BE202106105A BE1030002B1 BE 1030002 B1 BE1030002 B1 BE 1030002B1 BE 20216105 A BE20216105 A BE 20216105A BE 202106105 A BE202106105 A BE 202106105A BE 1030002 B1 BE1030002 B1 BE 1030002B1
Authority
BE
Belgium
Prior art keywords
hpbcd
ciclesonide
budesonide
complex
prevention
Prior art date
Application number
BE20216105A
Other languages
English (en)
Other versions
BE1030002A1 (fr
Inventor
Natacha Rocks
Maurizio Passanisi
Didier Cataldo
Original Assignee
Aquilon Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquilon Pharmaceuticals filed Critical Aquilon Pharmaceuticals
Priority to BE20216105A priority Critical patent/BE1030002B1/fr
Priority to PCT/EP2022/086808 priority patent/WO2023118014A1/fr
Publication of BE1030002A1 publication Critical patent/BE1030002A1/fr
Application granted granted Critical
Publication of BE1030002B1 publication Critical patent/BE1030002B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Composition inhalable comprenant un complexe d'hydroxypropyl-bêta-cyclodextrine (HPBCD) ou d'un dérivé pharmaceutiquement acceptable de celle-ci et de budésonide ou de ciclésonide pour une utilisation dans la prévention topique ou le traitement topique d'une maladie virale respiratoire.
BE20216105A 2021-12-20 2021-12-29 Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire BE1030002B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BE20216105A BE1030002B1 (fr) 2021-12-29 2021-12-29 Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire
PCT/EP2022/086808 WO2023118014A1 (fr) 2021-12-20 2022-12-19 Compositions inhalables comprenant un complexe de hpbcd et de budésonide ou de ciclésonide pour le traitement ou la prévention d'une maladie virale respiratoire ou d'une inflammation induite par des lipopolysaccharides, en particulier une inflammation induite par lipopolysaccharides associée à une maladie virale respiratoire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE20216105A BE1030002B1 (fr) 2021-12-29 2021-12-29 Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire

Publications (2)

Publication Number Publication Date
BE1030002A1 BE1030002A1 (fr) 2023-07-04
BE1030002B1 true BE1030002B1 (fr) 2023-09-01

Family

ID=85157199

Family Applications (1)

Application Number Title Priority Date Filing Date
BE20216105A BE1030002B1 (fr) 2021-12-20 2021-12-29 Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire

Country Status (1)

Country Link
BE (1) BE1030002B1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894559A1 (fr) * 2006-09-01 2008-03-05 PARI Pharma GmbH Stabilisation de stéroides destinées à être inhalées
WO2021048322A1 (fr) * 2019-09-10 2021-03-18 Aquilon Pharmaceuticals Microparticules de type balle de golf destinées à être utilisées dans le traitement et la prévention de maladies pulmonaires
US20210346613A1 (en) * 2020-05-05 2021-11-11 Mahesh Kumar KHAITAN Controlled delivery device for treating coronavirus infections and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924774T2 (de) 1988-07-07 1996-05-02 Univ Pennsylvania Modulation von virus-wirtszell-wechselwirkungen unter verwendung von cyclischen oligosacchariden.
EP1655034A1 (fr) 2004-10-10 2006-05-10 Université de Liège Utilisation d'un composé de cyclodextrine pour le traitement et la prévention des maladies inflammatoires bronchiques.
EP2923702A1 (fr) 2014-03-28 2015-09-30 Universite De Liege Composition de cyclodextrine avec des dérivés de budésonide pour le traitement et la prévention d'une maladie inflammatoire pulmonaire
WO2019067145A1 (fr) 2017-08-28 2019-04-04 Asdera Llc Utilisation de cyclodextrines dans des maladies et des troubles impliquant un dérèglement des phospholipides
BE1027425B1 (fr) 2019-07-01 2021-02-08 Aquilon Pharmaceuticals Composition inhalable comprenant de la cyclodextrine a utiliser dans le traitement d’inflammations nasales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894559A1 (fr) * 2006-09-01 2008-03-05 PARI Pharma GmbH Stabilisation de stéroides destinées à être inhalées
WO2021048322A1 (fr) * 2019-09-10 2021-03-18 Aquilon Pharmaceuticals Microparticules de type balle de golf destinées à être utilisées dans le traitement et la prévention de maladies pulmonaires
US20210346613A1 (en) * 2020-05-05 2021-11-11 Mahesh Kumar KHAITAN Controlled delivery device for treating coronavirus infections and methods thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FLORENCE CARROUEL ET AL: "COVID-19: A Recommendation to Examine the Effect of Mouthrinses with b-Cyclodextrin Combined with Citrox in Preventing Infection and Progression", JOURNAL OF CLINICAL MEDICINE, vol. 9, no. 4, 15 April 2020 (2020-04-15), pages 1126, XP055759526, DOI: 10.3390/jcm9041126 *

Also Published As

Publication number Publication date
BE1030002A1 (fr) 2023-07-04

Similar Documents

Publication Publication Date Title
Guggenheimer et al. Dental management of the (solid) organ transplant patient
US8349820B2 (en) Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido
Muto et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3: 4 trial
FitzGerald et al. A Randomised Controlled Trial of High Dose, Inhaled Budesonide Versus Oral Prednisone in Patients Discharged from the Emergency Department following an Acute Asthma Exacerbation
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
WO2006044916A3 (fr) Utilisation d'inhibiteurs de la na+/k+-atpase et leurs antagonistes
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
JP6580053B2 (ja) 潰瘍性大腸炎の治療用医薬組成物
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
MA30779B1 (fr) Comprimes pediatriques de capecitabine
MA52154B1 (fr) Composition pharmaceutique pour l'anémie
JP2021020945A5 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物
RU2007138263A (ru) Противовоспалительные соединения
FitzGerald et al. Safety of as-needed budesonide-formoterol in mild asthma: data from the two phase III SYGMA studies
BE1030002B1 (fr) Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire
BE1029585B1 (fr) Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire
JP2008533079A5 (fr)
Park et al. Efficacy and tolerability of GCSB-5 for hand osteoarthritis: a randomized, controlled trial
Sane et al. Is post-operative antibiotic therapy justified for surgical removal of mandibular third molar? A comparative study
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
Omoregie et al. Methotrexate-induced erythema multiforme: a case report and review of the literature
Aravena et al. Assessment of the bioavailability of an antibiotic prophylactic protocol in patients undergoing third molar surgery
Cenderello et al. COVID-19 treatment in the older people: a brief clinical review
Al-Mashhadane Uses and Misuses of Antibiotic in Dental Practice. A review.

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20230901